The present application demonstrates our new efforts emphasize disease sites beyond melanoma, where institutional expertise and minority patient accrual is feasible. The Head and Neck Cancer Program, Thoracic Oncology Program, and Gl Cancer Program have been major foci of our efforts in ECOG over the past several years, and we have succeeded to increase our accrual in these disease areas, to reapportion institutional activity. In these disease areas where we have demonstrated significantly greater accrual over the past 3 years, there is a greater opportunity to achieve improved levels of minority accrual, and these Disease Program efforts are coupled with several new and more rewarding initiatives in relation to minority outreach, that are described below and in the following competitive renewal application. These broader disease related efforts over the past several years have included recruitment of several leading investigators to the Head and Neck Cancer Program (A Argiris) and Hematologic Malignancies Program (P. Chaudhary, M. Mapara, M. Boyziadis), as well as the realignment of the Breast Program toward ECOG, with the appointment of A. Brufsky as Breast Program Director, which will increase and strengthen the effort to bring leading clinical investigations of the ECOG to the underserved minority African American populations of Pittsburgh and the surrounding areas of Western PA.

Agency
National Institute of Health (NIH)
Institute
National Cancer Institute (NCI)
Type
Cooperative Clinical Research--Cooperative Agreements (U10)
Project #
5U10CA039229-24
Application #
7617971
Study Section
Subcommittee G - Education (NCI)
Program Officer
Mooney, Margaret M
Project Start
1985-06-01
Project End
2010-04-30
Budget Start
2009-05-01
Budget End
2010-04-30
Support Year
24
Fiscal Year
2009
Total Cost
$250,100
Indirect Cost
Name
University of Pittsburgh
Department
Internal Medicine/Medicine
Type
Schools of Medicine
DUNS #
004514360
City
Pittsburgh
State
PA
Country
United States
Zip Code
15213
Moots, Paul L; O'Neill, Anne; Londer, Harold et al. (2018) Preradiation Chemotherapy for Adult High-risk Medulloblastoma: A Trial of the ECOG-ACRIN Cancer Research Group (E4397). Am J Clin Oncol 41:588-594
Zhou, Jun; Mahoney, Kathleen M; Giobbie-Hurder, Anita et al. (2017) Soluble PD-L1 as a Biomarker in Malignant Melanoma Treated with Checkpoint Blockade. Cancer Immunol Res 5:480-492
Agarwala, Sanjiv S; Lee, Sandra J; Yip, Waiki et al. (2017) Phase III Randomized Study of 4 Weeks of High-Dose Interferon-?-2b in Stage T2bNO, T3a-bNO, T4a-bNO, and T1-4N1a-2a (microscopic) Melanoma: A Trial of the Eastern Cooperative Oncology Group-American College of Radiology Imaging Network Cancer Research Gro J Clin Oncol 35:885-892
Bakhru, Pearl; Zhu, Meng-Lei; Wang, Hsing-Hui et al. (2017) Combination central tolerance and peripheral checkpoint blockade unleashes antimelanoma immunity. JCI Insight 2:
Wilson, Melissa A; Zhao, Fengmin; Khare, Sanika et al. (2016) Copy Number Changes Are Associated with Response to Treatment with Carboplatin, Paclitaxel, and Sorafenib in Melanoma. Clin Cancer Res 22:374-82
Neal, Joel W; Dahlberg, Suzanne E; Wakelee, Heather A et al. (2016) Erlotinib, cabozantinib, or erlotinib plus cabozantinib as second-line or third-line treatment of patients with EGFR wild-type advanced non-small-cell lung cancer (ECOG-ACRIN 1512): a randomised, controlled, open-label, multicentre, phase 2 trial. Lancet Oncol 17:1661-1671
Langer, Corey J; Socinski, Mark A; Patel, Jyoti D et al. (2016) Isolating the Role of Bevacizumab in Elderly Patients With Previously Untreated Nonsquamous Non-Small Cell Lung Cancer: Secondary Analyses of the ECOG 4599 and PointBreak Trials. Am J Clin Oncol 39:441-7
Schneider, Bryan P; O'Neill, Anne; Shen, Fei et al. (2015) Pilot trial of paclitaxel-trastuzumab adjuvant therapy for early stage breast cancer: a trial of the ECOG-ACRIN cancer research group (E2198). Br J Cancer 113:1651-7
Willis, Scooter; De, Pradip; Dey, Nandini et al. (2015) Enriched transcription factor signatures in triple negative breast cancer indicates possible targeted therapies with existing drugs. Meta Gene 4:129-41
Schneider, Bryan P; Li, Lang; Radovich, Milan et al. (2015) Genome-Wide Association Studies for Taxane-Induced Peripheral Neuropathy in ECOG-5103 and ECOG-1199. Clin Cancer Res 21:5082-5091

Showing the most recent 10 out of 59 publications